Stanford-monitored trials on 30 special forces veterans in Mexico show ibogaine reduced PTSD symptoms, but mechanism remains unknown.
Key Takeaways
Single ibogaine sessions (up to 14mg/kg) produced measurable reductions in PTSD-linked brain waves still present one month post-treatment in veteran trial participants.
Mechanism is unclear: ibogaine does not primarily act on 5-HT2A receptors; candidate pathways include kappa-opioid receptors and neurotrophin-driven neuroplasticity.
UC researchers created a trip-free synthetic analog that reduced alcohol and heroin-seeking in rats, suggesting the psychedelic experience may not be required.
Cardiac risk is real; participants received IV magnesium sulfate during sessions and required continuous medical monitoring throughout.
Trump signed an April 2026 executive order directing FDA to expedite psychedelic review and allocating $50M federal funding specifically for ibogaine research; Texas committed another $50M in 2025.
Hacker News Comment Review
Commenters questioned why ibogaine is prioritized over compounds with comparable psychological effects but fewer cardiac risks, naming salvia, LSD, and psilocybin as alternatives.
No substantive technical or mechanistic discussion beyond comparator drug suggestions; the thread is sparse.
